 |
21 Diseases |  |
0 Trials |
|
0 Trials |  |
30 News |  |
- | toreforant (JNJ-38518168) / J&J
Biomarker, Clinical, P2 data, Journal: Toreforant, an orally active histamine H-receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate: mechanism of action results from a phase 2, multicenter, randomized, double-blind, placebo-controlled synovial biopsy study. (Pubmed Central) - Aug 15, 2019
Synovial expression of interleukins-17A/17F was minimal. Limited sample size warrants cautious interpretation.
- | toreforant (JNJ-38518168) / J&J
P2a data, Journal: A Phase 2a Study of Toreforant, a Histamine H Receptor Antagonist, in Eosinophilic Asthma. (Pubmed Central) - Aug 1, 2019
P2a
Limited sample size warrants cautious interpretation. No abstract available
- toreforant (JNJ-38518168) / J&J
Phase classification: A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate (clinicaltrials.gov) - Mar 24, 2017
P2b, N=272, Terminated, Sponsor: Janssen Research & Development, LLC
No abstract available Phase classification: P2 --> P2b
- |||| toreforant (JNJ-38518168) / J&J
Trial completion: A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis (clinicaltrials.gov) - Jul 12, 2016
P2, N=62, Completed, Sponsor: Janssen Research & Development, LLC
Phase classification: P2 --> P2b Recruiting --> Completed
- || toreforant (JNJ-38518168) / J&J
Trial primary completion date: A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis (clinicaltrials.gov) - Dec 12, 2015
P2, N=66, Recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Completed Trial primary completion date: Sep 2015 --> Feb 2016
- |||| toreforant (JNJ-38518168) / J&J
Trial completion: A Study of JNJ-38518168 in Symptomatic Adult Participants With Uncontrolled, Persistent Asthma (clinicaltrials.gov) - Oct 2, 2015
P2, N=166, Completed, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Sep 2015 --> Feb 2016 Active, not recruiting --> Completed
- ||| toreforant (JNJ-38518168) / J&J
Enrollment closed, Trial primary completion date: A Study of JNJ-38518168 in Symptomatic Adult Participants With Uncontrolled, Persistent Asthma (clinicaltrials.gov) - Mar 3, 2015
P2, N=165, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Jul 2015
- |||| toreforant (JNJ-38518168) / J&J
Enrollment open: A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis (clinicaltrials.gov) - Feb 3, 2015
P2, N=66, Recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Jul 2015 Not yet recruiting --> Recruiting
- ||||| toreforant (JNJ-38518168) / J&J
New P2 trial: A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis (clinicaltrials.gov) - Nov 20, 2014
P2, N=66, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- toreforant (JNJ-38518168) / J&J
Trial termination, Trial primary completion date, Biopsy: A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy (clinicaltrials.gov) - Aug 1, 2014
P2, N=25, Terminated, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Recruiting --> Terminated | Trial primary completion date: Oct 2015 --> Jul 2014; The study was stopped due to lack of efficacy in a study conducted in a similar population,38518168ARA2002-NCT01679951.
- | toreforant (JNJ-38518168) / J&J
Trial termination: A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate (clinicaltrials.gov) - Jul 2, 2014
P2, N=272, Terminated, Sponsor: Janssen Research & Development, LLC
Recruiting --> Terminated | Trial primary completion date: Oct 2015 --> Jul 2014; The study was stopped due to lack of efficacy in a study conducted in a similar population,38518168ARA2002-NCT01679951. Active, not recruiting --> Terminated; The decision was made to prematurely discontinue this trial due to lack of efficacy.
- toreforant (JNJ-38518168) / J&J
Trial primary completion date, Biopsy: A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy (clinicaltrials.gov) - May 6, 2014
P2, N=25, Recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Terminated; The decision was made to prematurely discontinue this trial due to lack of efficacy. Trial primary completion date: Apr 2014 --> Oct 2015
- ||| toreforant (JNJ-38518168) / J&J
Enrollment closed: A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate (clinicaltrials.gov) - Feb 5, 2014
P2, N=272, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Apr 2014 --> Oct 2015 Recruiting --> Active, not recruiting
- toreforant (JNJ-38518168) / J&J
Trial completion: A Study to Evaluate the Pharmacokinetics of JNJ-38518168 in Patients With Mild and Moderate Hepatic Impairment Compared With Patients With Normal Hepatic Function (clinicaltrials.gov) - Dec 26, 2013
P1, N=28, Completed, Sponsor: Janssen Research & Development, LLC
Recruiting --> Active, not recruiting Recruiting --> Completed
- toreforant (JNJ-38518168) / J&J
New P1 trial: A Study to Investigate the Absorption, Metabolism, and Excretion of JNJ-38518168 After a Single Oral Dose in Healthy Male Participants. (clinicaltrials.gov) - Oct 21, 2013
P1, N=6, Completed, Sponsor: Janssen Research & Development, LLC
- toreforant (JNJ-38518168) / J&J
Trial completion: A Study to Investigate the Absorption, Metabolism, and Excretion of JNJ-38518168 After a Single Oral Dose in Healthy Male Participants. (clinicaltrials.gov) - Oct 21, 2013
P1, N=6, Completed, Sponsor: Janssen Research & Development, LLC
Recruiting --> Completed Not yet recruiting --> Completed
- ||| toreforant (JNJ-38518168) / J&J
Trial initiation date: A Study of JNJ-38518168 in Symptomatic Adult Participants With Uncontrolled, Persistent Asthma (clinicaltrials.gov) - Oct 3, 2013
P2, N=160, Recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Completed Initiation date: Jun 2013 --> Sep 2013
- |||| toreforant (JNJ-38518168) / J&J
Enrollment open: A Study of JNJ-38518168 in Symptomatic Adult Participants With Uncontrolled, Persistent Asthma (clinicaltrials.gov) - Jun 20, 2013
P2, N=160, Recruiting, Sponsor: Janssen Research & Development, LLC
Initiation date: Jun 2013 --> Sep 2013 Not yet recruiting --> Recruiting
- | toreforant (JNJ-38518168) / J&J
Enrollment open, Biopsy: A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy (clinicaltrials.gov) - Jun 2, 2013
P2, N=24, Recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- toreforant (JNJ-38518168) / J&J
New P1 trial: A Study to Evaluate the Pharmacokinetics of JNJ-38518168 in Patients With Mild and Moderate Hepatic Impairment Compared With Patients With Normal Hepatic Function (clinicaltrials.gov) - May 27, 2013
P1, N=28, Completed, Sponsor: Janssen Research & Development, LLC
- | toreforant (JNJ-38518168) / J&J
New P2 trial, Biopsy: A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy (clinicaltrials.gov) - May 22, 2013
P2, N=24, Recruiting, Sponsor: Janssen Research & Development, LLC
- ||||| toreforant (JNJ-38518168) / J&J
New P2 trial: A Study of JNJ-38518168 in Symptomatic Adult Participants With Uncontrolled, Persistent Asthma (clinicaltrials.gov) - Apr 2, 2013
P2, N=160, Recruiting, Sponsor: Janssen Research & Development, LLC
- toreforant (JNJ-38518168) / J&J
Enrollment change: Effect of Ketoconazole on the Pharmacokinetics of JNJ-38518168 in Healthy Volunteers (clinicaltrials.gov) - Mar 17, 2013
P1, N=33, Completed, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting N=48 --> 33
- | toreforant (JNJ-38518168) / J&J
Trial completion: Effect of Ketoconazole on the Pharmacokinetics of JNJ-38518168 in Healthy Volunteers (clinicaltrials.gov) - Mar 17, 2013
P1, N=33, Completed, Sponsor: Janssen Research & Development, LLC
N=48 --> 33 Recruiting --> Completed
- | toreforant (JNJ-38518168) / J&J
New P1 trial: Effect of Ketoconazole on the Pharmacokinetics of JNJ-38518168 in Healthy Volunteers (clinicaltrials.gov) - Sep 19, 2012
P1, N=33, Completed, Sponsor: Janssen Research & Development, LLC
- ||||| toreforant (JNJ-38518168) / J&J
New P2 trial: A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate (clinicaltrials.gov) - Sep 4, 2012
P2, N=272, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
- ||| toreforant (JNJ-38518168) / J&J
Trial completion: A Study of the Safety and Pharmacokinetics of JNJ-38518168 in Japanese and Caucasian Male Participants and the Effect of JNJ-38518168 on the Blood Levels of Midazolam (clinicaltrials.gov) - Aug 5, 2012
P1, N=94, Completed, Sponsor: Janssen Research & Development, LLC
Recruiting --> Completed Active, not recruiting --> Completed
- toreforant (JNJ-38518168) / J&J
Enrollment change: A Study to Investigate How JNJ-38518168 May Affect the Plasma Levels of Methotrexate in Rheumatoid Arthritis Participants (clinicaltrials.gov) - Dec 22, 2011
P1, N=20, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Active, not recruiting --> Completed N=16 --> 20
- | toreforant (JNJ-38518168) / J&J
New P1 trial: A Study to Investigate How JNJ-38518168 May Affect the Plasma Levels of Methotrexate in Rheumatoid Arthritis Participants (clinicaltrials.gov) - Oct 11, 2011
P1, N=20, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- ||| toreforant (JNJ-38518168) / J&J
New P1 trial: A Study of the Safety and Pharmacokinetics of JNJ-38518168 in Japanese and Caucasian Male Participants and the Effect of JNJ-38518168 on the Blood Levels of Midazolam (clinicaltrials.gov) - Sep 26, 2011
P1, N=94, Completed, Sponsor: Janssen Research & Development, LLC